Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.
IPO Year:
Exchange: NYSE
Website: cardinalhealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2025 | $130.00 → $144.00 | Hold → Buy | TD Cowen |
| 1/7/2025 | $140.00 | In-line → Outperform | Evercore ISI |
| 1/6/2025 | $132.00 → $145.00 | Neutral → Buy | BofA Securities |
| 12/13/2024 | $101.00 → $127.00 | Underweight → Equal Weight | Wells Fargo |
| 12/4/2024 | $139.00 | Outperform | Mizuho |
| 2/26/2024 | $125.00 | Outperform | Leerink Partners |
| 2/9/2024 | Hold → Buy | Argus | |
| 1/3/2024 | $117.00 | Overweight | Barclays |
| 12/14/2023 | $96.00 | Underweight | Wells Fargo |
| 7/10/2023 | $100.00 | Outperform → In-line | Evercore ISI |
DUBLIN, Ohio, Nov. 5, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on January 15, 2025 to shareholders of record at the close of business on January 2, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuc
Revenue decreased 4% to $52.3 billion; revenue increased 15% excluding the impact of the previously communicated large customer contract expirationGAAP1 operating earnings were $568 million; GAAP diluted EPS was $1.70Non-GAAP operating earnings increased 12% to $625 million, driven by significant growth in Pharmaceutical and Specialty Solutions segment profitNon-GAAP diluted EPS increased 9% to $1.88Fiscal year 2025 non-GAAP EPS guidance2 raised to $7.75 to $7.90, from $7.55 to $7.70DUBLIN, Ohio, Nov. 1, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2025 revenue of $52.3 billion, a decrease of 4% from the first quarter of fiscal year 2024. First qu
DUBLIN, Ohio, Aug. 15, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on October 15, 2024 to shareholders of record at the close of business on October 1, 2024. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business
Fourth quarter revenue increased 12% to $59.9 billionFourth quarter GAAP1 operating earnings were $401 million and GAAP diluted EPS was $0.96Fourth quarter non-GAAP operating earnings increased 14% to $605 million and non-GAAP diluted EPS increased 29% to $1.84Fiscal Year 2024 operating cash flow and adjusted free cash flow reached all-time highs of $3.8 billion and $3.9 billion, respectivelyFiscal year 2025 non-GAAP EPS guidance raised to $7.55 to $7.70, from at least $7.50DUBLIN, Ohio, Aug. 14, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported fourth quarter fiscal year 2024 revenues of $59.9 billion, an increase of 12% from the prior year. GAAP operating earnings were $401 m
DUBLIN, Ohio, May 7, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5056 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2024 to shareholders of record at the close of business on July 1, 2024. About Cardinal Health Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With more than 50 year
Revenue increased 9% to $54.9 billionGAAP1 operating earnings were $367 million; GAAP diluted EPS was $1.05Non-GAAP operating earnings increased 10% to $666 million; non-GAAP diluted EPS increased 20% to $2.08Fiscal year 2024 non-GAAP EPS guidance2 raised and narrowed to $7.30 to $7.40, from $7.20 to $7.35Company provides preliminary fiscal year 2025 non-GAAP EPS guidance of at least $7.50DUBLIN, Ohio, May 2, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported third quarter fiscal year 2024 revenues of $54.9 billion, an increase of 9% from the third quarter of fiscal year 2023. Third quarter GAAP operating earnings were $367 million and GAAP diluted earnings per share (EPS) were
DUBLIN, Ohio, Feb. 6, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5006 per share out of the Company's capital surplus. The dividend will be payable on April 15, 2024 to shareholders of record at the close of business on April 1, 2024. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business, ope
Revenue increased 12% to $57.4 billionGAAP1 operating earnings were $482 million; GAAP diluted EPS was $1.43Non-GAAP operating earnings increased 20% to $562 million; non-GAAP diluted EPS increased 38% to $1.82Fiscal 2024 non-GAAP EPS guidance raised to $7.20 to $7.35, from $6.75 to $7.002,3Fiscal 2024 non-GAAP adjusted free cash flow guidance raised to ~$2.5 billion, from ~$2.0 billionCardinal Health to acquire Specialty Networks, a technology-enabled multi-specialty group purchasing and practice enhancement organizationDUBLIN, Ohio, Feb. 1, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported second quarter fiscal 2024 revenue of $57.4 billion, an increase of 12% from the second
Progress achieved on company's ongoing business and portfolio review Completed review of growth businesses within the Medical Segment: investing in and further developing at-Home Solutions and OptiFreight® Logistics as part of the company's portfolio for long-term growth and value creationReview of Global Medical Products and Distribution business continues, with focus on driving operational performance through the Medical Improvement PlanReorganizing leadership structure to continue company's simplification efforts, prioritize core operational execution and drive efficiencies, accountability and transparencyUpdated enterprise operating and segment reporting structure, effective January 1, 2
DUBLIN, Ohio, Nov. 14, 2023 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5006 per share out of the Company's capital surplus. The dividend will be payable on January 15, 2024 to shareholders of record at the close of business on January 2, 2024. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in busines
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
New facility will be outfitted with latest robotics and automation technologies DUBLIN, Ohio, Jan. 14, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced construction is underway on a new distribution center in Fort Worth, Texas, which will support its at-Home Solutions business, a leading medical supplies provider that serves more than 5 million patients annually in the United States. The new 340,000 square foot distribution center will consolidate its two existing warehouses into one larger facility, creating approximately 74,000 additional square feet of inventory ca
RPM International Inc. (NYSE:RPM) today announced the appointment of three individuals, Craig S. Morford, Christopher L. Mapes and Julie A. Beck, to its board of directors. These appointments reflect RPM's ongoing commitment to expanding the expertise, diversity and leadership capabilities of its board as the company continues to drive long-term growth and shareholder value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113146614/en/Christopher L. Mapes (Photo: Business Wire) The appointments of Mr. Morford and Mr. Mapes are effective immediately, and Ms. Beck's term is set to commence on April 7, 2025. With these additions,
DUBLIN, Ohio, Dec. 19, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2025 on January 30, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern. To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months. About Cardinal Health Cardin
LEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to license its proprietary technology to expand its leadership in direct-from-whole-blood detection of sepsis-causing pathogens. T2 Biosystems' proprietary technology is a key component of its FDA-cleared products, including the first and only products able to detect sepsis-causing pathogens directly from whole blood. T2 Biosystems' expanded business model is intended to generate non-dilutive capital through licensing agreements that provide access to the Company's patente
Next generation of the Kendall™ SCD Series delivers an all-in-one solution for deep vein thrombosis and pulmonary embolism prevention DUBLIN, Ohio, Nov. 20, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today the U.S. launch of its Kendall SCD SmartFlow™ Compression System, the next generation of the Kendall™ Compression Series offering an enhanced clinician and patient experience. Featuring clinically proven technology that delivers customized, intermittent pneumatic compression (IPC) to increase blood flow1 in at-risk patients, the Kendall SCD SmartFlow™ System is designed to help prevent venous thromboembolism (VTE) events, as well as enhance blood circulation and treat pain a
Cardinal Health to acquire Advanced Diabetes Supply Group Court Square Capital Partners ("Court Square"), a leading middle-market private equity company, announced today it has entered a definitive agreement in the sale of Advanced Diabetes Supply® Group ("ADSG", or "Company") to Cardinal Health (NYSE:CAH). Court Square originally acquired the Company in December 2020. Headquartered in Carlsbad, CA, ADSG is a national distributor of Durable Medical Equipment ("DME") specializing in diabetes supplies. The Company currently serves approximately 500,000 patients and specializes in the home delivery of diabetes products including continuous glucose monitoring ("CGM") devices and other testi
Southlake, Texas, Nov. 11, 2024 (GLOBE NEWSWIRE) -- GI Alliance (GIA) announced today that it has entered into a definitive agreement with Cardinal Health (NYSE:CAH) through which Cardinal Health will acquire a majority stake in GIA, a physician-led, national management services organization supporting independent gastroenterology practices from a combination of GIA physician owners and funds managed by affiliates of Apollo (NYSE:APO). The transaction values GI Alliance at $3.9 billion. "GI Alliance and Cardinal Health are aligned in our shared vision to build a physician-led, national specialty healthcare platform that will be the preferred choice for patients seeking dependable, high
Acquisition of a majority stake in GI Alliance, the country's leading gastroenterology management services organization, to accelerate Cardinal Health's multi-specialty growth strategy Acquisition of the Advanced Diabetes Supply Group, a leading national direct-to-patient provider of diabetes medical supplies, to accelerate Cardinal Health's at-Home Solutions growth strategyCompany announces plan to hold Investor Day in June 2025DUBLIN, Ohio, Nov. 11, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that it has entered into definitive agreements to acquire two companies that accelerate Cardinal Health's strategic growth areas and that will enhance patient care. The company als
DUBLIN, Ohio, Nov. 5, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on January 15, 2025 to shareholders of record at the close of business on January 2, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuc
Revenue decreased 4% to $52.3 billion; revenue increased 15% excluding the impact of the previously communicated large customer contract expirationGAAP1 operating earnings were $568 million; GAAP diluted EPS was $1.70Non-GAAP operating earnings increased 12% to $625 million, driven by significant growth in Pharmaceutical and Specialty Solutions segment profitNon-GAAP diluted EPS increased 9% to $1.88Fiscal year 2025 non-GAAP EPS guidance2 raised to $7.75 to $7.90, from $7.55 to $7.70DUBLIN, Ohio, Nov. 1, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2025 revenue of $52.3 billion, a decrease of 4% from the first quarter of fiscal year 2024. First qu
8-K - CARDINAL HEALTH INC (0000721371) (Filer)
8-K - CARDINAL HEALTH INC (0000721371) (Filer)
8-K - CARDINAL HEALTH INC (0000721371) (Filer)
8-K - CARDINAL HEALTH INC (0000721371) (Filer)
424B5 - CARDINAL HEALTH INC (0000721371) (Filer)
FWP - CARDINAL HEALTH INC (0000721371) (Subject)
424B3 - CARDINAL HEALTH INC (0000721371) (Filer)
8-K - CARDINAL HEALTH INC (0000721371) (Filer)
S-8 POS - CARDINAL HEALTH INC (0000721371) (Filer)
S-8 POS - CARDINAL HEALTH INC (0000721371) (Filer)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
RPM International Inc. (NYSE:RPM) today announced the appointment of three individuals, Craig S. Morford, Christopher L. Mapes and Julie A. Beck, to its board of directors. These appointments reflect RPM's ongoing commitment to expanding the expertise, diversity and leadership capabilities of its board as the company continues to drive long-term growth and shareholder value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113146614/en/Christopher L. Mapes (Photo: Business Wire) The appointments of Mr. Morford and Mr. Mapes are effective immediately, and Ms. Beck's term is set to commence on April 7, 2025. With these additions,
DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1. Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries. Mr. Azelby has previously served as President and Chief Executive Officer of Eliem Therapeutics, and prior to Eliem, he was the Chief Executive Officer of Alder BioPharmac
Revenue increased 13% to $49.6 billionGAAP1 operating earnings were $137 million, GAAP diluted EPS were $0.40Non-GAAP operating earnings decreased 20% to $423 million due to a decline in Medical segment profit, partially offset by an increase in Pharmaceutical segment profit; non-GAAP diluted EPS decreased 7% to $1.20Company reaffirmed fiscal year 2023 non-GAAP EPS guidanceDUBLIN, Ohio, Nov. 4, 2022 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported first quarter fiscal year 2023 revenues of $49.6 billion, an increase of 13% from the first quarter of last year. First quarter GAAP operating earnings were $137 million, including a non-cash, pre-tax goodwill impairment charge of $154 mil
Adds Four New Independent Directors to the Board Forms New Business Review Committee to Evaluate Portfolio and Operations DUBLIN, Ohio, Sept. 6, 2022 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced initiatives aimed at positioning the Company for long-term success, building on Cardinal Health's previously announced growth plans. These initiatives have benefited from input received from Elliott Investment Management L.P. ("Elliott"). In connection with these initiatives, Elliott has also entered into a cooperation agreement with Cardinal Health, and Elliott's Steven Barg will join the Company's Board of Directors.
CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel."I am pleased to welcome Jorge to Moderna as our Chief Financial Officer and as a member of the Executive Committee," said Mr. Bancel. "As we grow and scale the company globally, Jorge's experience leading the financial functions of multinational healthcare companies will be an asset to our team. Jorge's passion for sustainabilit
Believes Nominees Have the Independent Perspectives, Differentiated Real Estate Investment Experience and Shareholder-Focused Mindsets Needed to Help Reverse Lexington's Chronic Underperformance Objective and Independent New Voices are Needed in the Boardroom to Oversee Leadership Transition Process and Full Review to Determine the Right Path Forward for LXP LXP's Total Shareholder Returns Have Underperformed Proxy Peers and Industrial Peers by Nearly 500% During CEO's 18-year Tenure1 Today Land & Buildings Investment Management, LLC (together with its affiliates, "Land & Buildings"), a significant shareholder of Lexington Realty Trust ("LXP," "Lexington" or the "Company") (NYSE:LXP), an
CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Jon Giacomin to the Company's Board of Directors, effective May 7, 2021. The Company also announced that Wayne Mackie resigned as a member of the Company's Board of Directors effective May 7, 2021. Mr. Mackie's resignation was not due to any disagreement with the Company on any matter relating to its operations, policies or practices. "Jon is a proven leader who brings signifi
NEW YORK & LOS ANGELES--(BUSINESS WIRE)--RMG Acquisition Corp. (the “Company”) announced the nomination of Paul Williams for election at a special meeting of stockholders of the Company to serve on the board of directors of the combined company upon consummation of the previously announced merger between the Company and Romeo Systems, Inc. (“Romeo Power”). Prior to his retirement in 2018, Mr. Williams served as a Partner and Managing Director of Major, Lindsey & Africa, LLC, an executive recruiting firm, where he conducted searches for board members, CEOs and senior legal executives from 2005 to 2018. He also served as Director of Global Diversity Search, assisting legal organizati
TD Cowen upgraded Cardinal Health from Hold to Buy and set a new price target of $144.00 from $130.00 previously
Evercore ISI upgraded Cardinal Health from In-line to Outperform and set a new price target of $140.00
BofA Securities upgraded Cardinal Health from Neutral to Buy and set a new price target of $145.00 from $132.00 previously
Wells Fargo upgraded Cardinal Health from Underweight to Equal Weight and set a new price target of $127.00 from $101.00 previously
Mizuho resumed coverage of Cardinal Health with a rating of Outperform and set a new price target of $139.00
Leerink Partners initiated coverage of Cardinal Health with a rating of Outperform and set a new price target of $125.00
Argus upgraded Cardinal Health from Hold to Buy
Barclays initiated coverage of Cardinal Health with a rating of Overweight and set a new price target of $117.00
Wells Fargo initiated coverage of Cardinal Health with a rating of Underweight and set a new price target of $96.00
Evercore ISI downgraded Cardinal Health from Outperform to In-line and set a new price target of $100.00